uniQure Eyes 2029 Runway as FDA Talks for Huntington's Gene Therapy Continue

uniQure’s full-year 2025 financial results reveal a company in a rare position of fiscal strength within the gene therapy sector, yet one facing a complex regulatory gauntlet for its most high-profile asset. With approximately $622.5 million in cash and investments as of December 31, 2025, the company has secured a capital runway extending into the second half of 2029. This multi-year cushion provides uniQure with the necessary leverage to navigate the protracted discussions with the U.S. Food and Drug Administration (FDA) regarding AMT-130, its experimental gene therapy for Huntington’s disease. In an industry where many pre-commercial firms are operating on less than 12 months of cash, uniQure’s four-year runway is a significant competitive advantage that allows for strategic patience.

The central tension in uniQure’s current narrative lies in the disconnect between clinical data and regulatory alignment. CEO Matt Kapusta highlighted 36-month data for AMT-130 as "compelling" and "durable," suggesting the therapy could be the first disease-modifying treatment for Huntington’s. However, the recent Type A meeting with the FDA did not result in a clear consensus on the approval pathway. This suggests that the agency may be seeking more robust Phase III evidence or specific clinical endpoints that differ from the company’s current projections. The upcoming Type B meeting in the second quarter of 2026 will be a critical inflection point, as it will likely define whether uniQure can pursue an accelerated approval path or must commit to a larger, more expensive Phase III trial.

“

With approximately $622.5 million in cash and investments as of December 31, 2025, the company has secured a capital runway extending into the second half of 2029.

The regulatory hurdles for Huntington’s disease are notoriously high. Unlike some rare diseases where a single protein biomarker can serve as a surrogate endpoint, Huntington’s involves complex neurodegeneration that requires sophisticated measurement of motor and cognitive function over time. The FDA’s cautious stance reflects a broader trend of increased scrutiny on gene therapies, particularly those targeting the central nervous system. For uniQure, the challenge is to prove that the observed clinical benefits translate directly into meaningful quality-of-life improvements for patients. The company is currently evaluating Phase III development considerations, which indicates they are preparing for a more rigorous clinical validation phase if the FDA remains unconvinced by the existing dataset.

While AMT-130 remains the primary driver of market sentiment, uniQure is successfully diversifying its clinical risk across a broader portfolio. The completion of enrollment for the first cohort in the Phase I/IIa study of AMT-260 for refractory mesial temporal lobe epilepsy marks a significant milestone. With additional clinical data expected in the first half of 2026, this program offers a secondary catalyst that could decouple the company’s valuation from the singular success of the Huntington’s program. Furthermore, the updated data for AMT-191 in Fabry disease demonstrates the versatility of uniQure’s platform, showing durable, dose-dependent enzyme activity that positions the company as a serious contender in the metabolic disorder space.